112 related articles for article (PubMed ID: 27818099)
1. How Dextran Sulfate Affects C1-inhibitor Activity: A Model for Polysaccharide Potentiation.
Dijk M; Holkers J; Voskamp P; Giannetti BM; Waterreus WJ; van Veen HA; Pannu NS
Structure; 2016 Dec; 24(12):2182-2189. PubMed ID: 27818099
[TBL] [Abstract][Full Text] [Related]
2. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease.
Beinrohr L; Harmat V; Dobó J; Lörincz Z; Gál P; Závodszky P
J Biol Chem; 2007 Jul; 282(29):21100-9. PubMed ID: 17488724
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional structure and molecular modelling of C1- inhibitor.
Perkins SJ
Behring Inst Mitt; 1993 Dec; (93):63-80. PubMed ID: 8172587
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional aspects of C1-inhibitor.
Bos IG; Hack CE; Abrahams JP
Immunobiology; 2002 Sep; 205(4-5):518-33. PubMed ID: 12396012
[TBL] [Abstract][Full Text] [Related]
5. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.
Bos IG; van Mierlo GJ; Bleeker WK; Rigter GM; te Velthuis H; Dickneite G; Hack CE
Int Immunopharmacol; 2001 Aug; 1(8):1583-95. PubMed ID: 11515821
[TBL] [Abstract][Full Text] [Related]
6. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
Bos IG; Lubbers YT; Roem D; Abrahams JP; Hack CE; Eldering E
J Biol Chem; 2003 Aug; 278(32):29463-70. PubMed ID: 12773530
[TBL] [Abstract][Full Text] [Related]
7. C1 Inhibitor as a glycoprotein: The influence of polysaccharides on its function and autoantibody target.
Ghannam A; Sellier P; Fain O; Martin L; Ponard D; Drouet C
Mol Immunol; 2016 Mar; 71():161-165. PubMed ID: 26897339
[TBL] [Abstract][Full Text] [Related]
8. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.
Cai S; Davis AE
J Immunol; 2003 Nov; 171(9):4786-91. PubMed ID: 14568956
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.
Wuillemin WA; te Velthuis H; Lubbers YT; de Ruig CP; Eldering E; Hack CE
J Immunol; 1997 Aug; 159(4):1953-60. PubMed ID: 9257861
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships.
Schoenfeld AK; Lahrsen E; Alban S
PLoS One; 2016; 11(10):e0165493. PubMed ID: 27783665
[TBL] [Abstract][Full Text] [Related]
11. Biological effects of C1 inhibitor.
Davis AE
Drug News Perspect; 2004 Sep; 17(7):439-46. PubMed ID: 15514703
[TBL] [Abstract][Full Text] [Related]
12. The native metastable fold of C1-inhibitor is stabilized by disulfide bonds.
Simonovic I; Patston PA
Biochim Biophys Acta; 2000 Aug; 1481(1):97-102. PubMed ID: 11004579
[TBL] [Abstract][Full Text] [Related]
13. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
Zahedi R; Wisnieski J; Davis AE
J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
[TBL] [Abstract][Full Text] [Related]
14. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
[TBL] [Abstract][Full Text] [Related]
15. C1 inhibitor: molecular and clinical aspects.
Cicardi M; Zingale L; Zanichelli A; Pappalardo E; Cicardi B
Springer Semin Immunopathol; 2005 Nov; 27(3):286-98. PubMed ID: 16267649
[TBL] [Abstract][Full Text] [Related]
16. Hydrodynamic data show that C1- inhibitor of complement forms compact complexes with C1-r and C1-s.
Perkins SJ
FEBS Lett; 1990 Oct; 271(1-2):89-92. PubMed ID: 2226818
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of the serpin domain of C1 inhibitor.
Coutinho M; Aulak KS; Davis AE
J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.
Murray-Rust TA; Kerr FK; Thomas AR; Wu T; Yongqing T; Ong PC; Quinsey NS; Whisstock JC; Wagenaar-Bos IC; Freeman C; Pike RN
Biochem J; 2009 Aug; 422(2):295-303. PubMed ID: 19522701
[TBL] [Abstract][Full Text] [Related]
19. A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex.
He S; Sim RB; Whaley K
FEBS Lett; 1997 Mar; 405(1):42-6. PubMed ID: 9094421
[TBL] [Abstract][Full Text] [Related]
20. Molecular defects in hereditary angioneurotic edema.
Bissler JJ; Aulak KS; Donaldson VH; Rosen FS; Cicardi M; Harrison RA; Davis AE
Proc Assoc Am Physicians; 1997 Mar; 109(2):164-73. PubMed ID: 9069585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
